Wednesday, February 15, 2012

Gene Therapy Meets Stem Cells


Gene Therapy Meets Stem Cells

Robert A. Sandhaus, M.D., Ph.D.
N Engl J Med 2012; 366:567-569 February 9, 2012


Stem cell–based therapies have the potential to repair and even correct the defects related to human diseases. Although tantalizing niche applications have moved forward in the clinical setting, progress seems to be slow, and ethical challenges have yet to be definitively addressed. The goal of developing pluripotent cells that can transmute to organ-specific maturity at our direction, and possibly cure many human diseases, has yet to be attained.
With recent advances, however, gene correction involving stem cells is closer to being within our grasp. Although techniques for correcting genetic abnormalities have been available in the laboratory for years, the tools for manipulating the genome tend to leave traces of unwanted genetic material within the cell or within the genes themselves. Recently, Yusa and colleagues described a tour-de-force study involving the correction of a single gene mutation in induced pluripotent stem cells (iPSCs) derived from patients' own dermal fibroblasts.1 (Since these stem cells are typically derived from a differentiated somatic cell, they differ from embryonic stem cells, which are derived from the early embryo.) Using techniques that appear to leave no residual sequences behind, these investigators replaced a mutated DNA sequence within patient-derived iPSCs with one encoding the normal gene product.
The authors chose to study alpha1-antitrypsin deficiency, which is caused by mutations in SERPINA1, the gene that encodes this serine protease inhibitor (PI). The “normal” variant of this gene (designated PI*M) differs from the most common, severely deficient genotype (PI*Z) by a single base pair, leading to the substitution of a single amino acid (Glu342Lys) in the alpha1-antitrypsin protein. The corrected iPSCs were stimulated to acquire the characteristics of hepatocytes, appropriately including the synthesis and secretion of normal alpha1-antitrypsin. After intrasplenic injection into mice these iPSC-derived, gene-corrected hepatocytes were shown to populate the liver of these mice and to maintain their hepatocyte-like and alpha1-antitrypsin–producing characteristics for many weeks.
Alpha1-antitrypsin deficiency is only one of many monogenic diseases that could be potential targets for this type of corrective approach. Yusa and colleagues go so far as to predict that, should this technology be found to be safe and effective, iPSCs derived from a person could be returned — corrected and hepatocyte-like — to that same person in approximately 4 months (Figure 1Figure 1Ameliorating Alpha1-Antitrypsin Deficiency.). Although it is difficult to achieve the dual goals of safety and efficacy for any new therapeutic agent, the use of genetically manipulated iPSCs as a form of therapy poses unique safety issues, some of which these investigators have addressed. For example, by using native stem cells (derived from a person's own somatic cells), these authors have taken important steps toward addressing concerns about the possible rejection of or reaction to these iPSC-derived hepatocytes.
Stem cells accumulate mutations throughout their genome as they multiply in culture. Some mutations are predictable and well characterized, whereas others appear to occur at random. Of concern is the possibility that an acquired mutation could possess oncogenic properties and lead to neoplasia. The authors offer two observations relative to these concerns: They compared the mutations acquired during growth in culture of both uncorrected iPSCs and gene-corrected iPSCs and found no important differences between the two. They also observed no cancers in the mice that had received the modified iPSCs after 2 weeks. Although these findings are reassuring, they represent only a first step toward documenting the safety of such procedures.
Assuming that the safety of iPSCs will eventually be addressed, we can speculate about the clinical application of patient-specific iPSC therapy in alpha1-antitrypsin deficiency as an illustrative example. Liver failure develops during the first months of life in about 2 to 3% of infants born with this deficiency. Use of corrected iPSCs to prevent disease in infants would probably involve intrauterine treatment or embryonic manipulation before implantation (though it might be easier to select an embryo that lacks the mutation, if one is available). Since this approach comes close to what could be considered embryonal stem cells, it would be safer to focus on instituting treatment later in the life of the affected person. More insidious liver injury, usually manifesting as cirrhosis, can occur at any time in persons with alpha1-antitrypsin deficiency. Destructive lung disease is the other major clinical manifestation of this disorder. It is well accepted that environmental factors increase the risks of lung and liver disease in patients with this disorder and that exposures during childhood are at least as important as exposures later in life. The “corrected iPSC” approach might therefore find its best application early in life, thus raising the stakes in terms of safety, especially with respect to the risk of neoplasia.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

Source Information

From National Jewish Health, Denver; and AlphaNet, Miami.

Tuesday, January 31, 2012

Polio consultant awarded prestigious Gates Vaccine Innovation Award

Wednesday, January 25, 2012
Polio consultant awarded prestigious Gates Vaccine Innovation Award
The Bill and Melinda Gates Foundation has awarded its prestigious Vaccine Innovation Award to polio consultant Dr Asm Amjad Hossain

<P align=justify><EM>The Bill and Melinda Gates Foundation has awarded its prestigious Vaccine Innovation Award to polio consultant Dr Asm Amjad Hossain</EM></P>
Melinda Gates, co-chair of the Bill and Melinda Gates Foundation, meets with Dr Asm Amjad Hossain, the recipient of the first Gates Vaccine Innovation Award
Bill and Melinda Gates Foundation
Dr Hossain, originally from Bangladesh and currently based in Nigeria supporting the country's polio eradication efforts there, received the Award from among 117 nominations encompassing a range of innovative solutions to increase vaccination coverage.

The Award is in direct recognition of Dr Hossain's innovative work in raising immunization coverage rates in key districts of Bangladesh, by institutionalising processees for registering pregnant women with expected delivery dates, annual schedules for vaccine sessions, and key active community outreach strategies. "(These innovations) show how looking at old problems in new ways can make a profound difference," said Mr Bill Gates, co-chair of the Bill and Melinda Gates Foundation. "Improvements like these are spreading to other locations because of the commitment and creativity of Dr Hossain and many others like him."

The Award was established by the Bill and Melinda Gates Foundation to recognize and celebrate revolutionary ways in which children in the poorest parts of the world are immunized. The Award winner is recognized with US$250,000 and personally acknowledged by Gates Foundation leadership.
source:
http://www.polioeradication.org/tabid/461/iid/191/Default.aspx



Sunday, January 8, 2012

VIRULENT STRAIN IN THE AIR : TDR TB


Publication: The Times Of India Delhi; Date: Jan 8, 2012; Section: Times Nation; Page: 10


 New, deadlier form of TB hits India 12 Totally Drug-Resistant Cases Of Killer Disease Isolated At Mumbai Hospital
Malathy Iyer TNN



Mumbai: Tuberculosis, which kills around 1,000 people every day in India, has acquired a deadlier edge. A new entity — ominously called Totally Drug-Resistant TB (TDRTB) — has been isolated in the fluid samples of 12 TB patients in the past three months alone at Hinduja Hospital at Mahim in Mumbai. The hospital’s laboratory has been certified by the World Health Organization (WHO) to test TB patients for drug resistance.

    While Iran first reported TDR-TB cases three years ago, India seems to be only the second country to report this deadly form of the disease. TDR-TB is the result of the latest mutation of the bacilli after Multi-Drug-Resistant TB (MDR-TB) and Extremely Drug-Resistant TB (XDR-TB) were diagnosed earlier.

    Even more worryingly for Mumbai, 10 of the 12 TDR-TB cases are from the city, while the other two are patients from Ratnagiri and Uttar Pradesh. One of the 12 patients has since died. India sees around 3-4 lakh deaths for all forms of TB each year, while the world saw 1.7 million deaths in 2009.

    As the full form of TDR-TB suggests, none of the known TB combination drugs work on the patient. All 12 showed resistance to 12 drugs. “The TB bacilli have obviously mutated. The emergence of TDR-TB has grave implications for public health,’’ said Hinduja Hospital’s Dr Zarir Udwadia, whose observations have been published in the latest issue of the US-based Clinical Infectious Diseases (CID) peer review journal. His team started isolating TDR-TB cases among patients with pulmonary TB in October last year.

    Dr Amita Athawale, who heads KEM Hospital’s chest department, said TDR-TB was a reality in India. “The cases we clinically isolate are just the tip of the iceberg,’’ she said. TB is one of the biggest killers in India, along with heart attack.

    Among tuberculosis patients, drug resistance develops mainly because patients fail to complete the 6-9 month first treatment phase. “They feel better within a couple of months of taking the drugs and so they stop taking them. However, the TB germs in the body are not completely vanquished and they again multiply,’’ said a senior BMC public health official.

Tuberculosis is one of the most fatal diseases in Mumbai, accounting for nearly 15% (8,953) of the deaths in 2010

• Left untreated, each person with active TB can infect 10 to 15 people a year


• TB is a contagious disease. Like the common cold, it spreads through the air


• Patients resistant to all first-line and second-line drugs are classified as having Totally Drug-Resistant TB (TDR-TB)

An estimated 1.7 million people died from TB worldwide in 2009


• About 3 lakh to 4 lakh die of TB each year in India


• It is believed that more than half the city’s TB patients seek treatment in the private sector